New hope for kids in shock: drug trial targets stubborn low blood pressure

NCT ID NCT07212686

ENROLLING_BY_INVITATION Disease control Sponsor: Todd Sweberg Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests a drug called Angiotensin II (Giapreza) in 30 children under 18 with life-threatening low blood pressure (vasodilatory shock) that hasn't improved with fluids or standard medicines. The goal is to see if the drug can safely raise blood pressure and reduce the need for other strong blood pressure medications. Participants receive the drug alongside usual care and are monitored for side effects and kidney blood flow.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASODILATORY SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cohen Children's Medical Center

    Queens, New York, 11101, United States

  • Cohen Children's Medical Center of Northwell Health

    New Hyde Park, New York, 11040, United States

Conditions

Explore the condition pages connected to this study.